2019
The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation
Haug V, Kollar B, Obed D, Kiwanuka H, Turk M, Wo L, Tasigiorgos S, Kueckelhaus M, Riella L, Pomahac B. The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation. Facial Plastic Surgery & Aesthetic Medicine 2019, 21: 278-285. PMID: 30998810, PMCID: PMC6646986, DOI: 10.1001/jamafacial.2019.0076.Peer-Reviewed Original ResearchConceptsAcute rejectionSubtherapeutic tacrolimus levelsClinical signsRejection episodesImmunosuppressive therapySubclinical rejectionTacrolimus levelsMedical recordsOdds ratioFacial transplantationDiagnostic valueSignificant associationSingle-center cohort studyLate rejection episodesProtocol skin biopsiesSecond posttransplant yearSymptoms of rejectionTacrolimus blood levelsSecond postoperative yearReliable clinical signFull facial transplantationPostoperative yearPosttransplant yearYears posttransplantationAllograft rejection
2018
Increased levels of circulating MMP3 correlate with severe rejection in face transplantation
Kollar B, Shubin A, Borges T, Tasigiorgos S, Win T, Lian C, Dillon S, Gu X, Wyrobnik I, Murphy G, Pomahac B, Libermann T, Riella L. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Scientific Reports 2018, 8: 14915. PMID: 30297859, PMCID: PMC6175842, DOI: 10.1038/s41598-018-33272-7.Peer-Reviewed Original ResearchConceptsSevere rejectionFace transplantationLarge independent patient cohortsAcute rejection episodesAnti-rejection treatmentFirst postoperative yearLongitudinal serum samplesNon-invasive candidate biomarkersViable treatment optionSOMAscan proteomics platformIndependent patient cohortsFace transplant recipientsRejection episodesPostoperative yearTransplant recipientsDevastating injuriesMMP3 levelsTransplant rejectionHistological gradePatient cohortTreatment optionsSurrogate markerMMP3 proteinCandidate biomarkersTransplantation